EUCTR2022-003725-22-DE进行中（未招募）1 期
Acute effect of iloprost (Ventavis®) inhalation in patients with exercise-induced pulmonary hypertension after a COVID-19 infection - IXite
Justus-Liebig-University Gießen0 个研究点目标入组 120 人开始时间: 2023年1月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All inclusion criteria will be verified after the signature of the informed consent on Day 0 and before the first right heart catheter exercise phase except criterion 5, which will be checked on Day 1 after the first right heart catheter exercise phase.
- •1. Patient must be = 18 years old
- •2. Signed informed consent
- •3. Patients with Post-COVID-19-Syndrome (persistent dyspnea longer than 12 weeks after a COVID-19 infection)
- •4. Patients with non-invasive signs of manifest or exercise-induced pulmonary hypertension (PH)
- •5. Exercise-induced PH determined by a mPAP/CO-slope > 3 mmHg/l/min between rest and exercise. This inclusion criterion will be checked on Day 1 on the basis of the result of the first RHC exercise phase.
- •6. Willingness of men and women of childbearing potential to use highly effective contraceptive methods.
- •Such methods include:
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- •o intravaginal
- •o transdermal
- •progestogen-only hormonal contraception associated with inhibition of ovulation:
- •o injectable
- •o implantable
- •intrauterine device (IUD)
- •intrauterine hormone-releasing system (IUS)
- •bilateral tubal occlusion
- •vasectomised partner
- •sexual abstinence
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •All exclusion criteria will be verified after the signature of the informed consent on Day 0, except criterion 1, which will be checked on Day 1 after the first right heart catheter exercise phase.
- •1. Hypercirculation (CI> 4.0 l/min/m2) or evidence of postcapillary PH (PAWP/CO-slope> 2 mm Hg/l/min). This exclusion criterion will be checked on Day 1 on the basis of the result of the first RHC exercise phase.
- •2. Preexisting clinically relevant lung disease (FEV 1< 60% pred., FVC < 60% pred., RV/TLC> 40%), radiologic signs of moderate to severe pulmonary emphysema
- •3. Severe coronary artery disease or unstable angina (history of surgery, history of coronary intervention two years prior to inclusion), history of myocardial infarction within the last six months, uncontrolled arterial hypertension, pulmonary hypertension due to pulmonary veno-occlusive disease, severe left ventricular hypertrophy, congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension, decompensated heart insufficiency if not under close medical control, history of stroke/transitory ischemic attack with the last three months prior to inclusion, systolic blood pressure below 85 mmHg, severe arrhythmias
- •4. Concomitant use of specific phosphodiesterase inhibitors (e.g. sildenafil, vardenafil, or tadalafil), endothelin antagonists (e.g. ambrisentan or macitentan), or intravenous prostacyclin; inhibitors of platelet aggregation or anticoagulants. The use of these substances needs to be stopped at least 8 weeks prior to study start.
- •5. Inability to perform cardiopulmonary exercise testing (CPET), including temporary orthopedic problems
- •6. Hemoglobin < lower limit of normal (LLN)
- •7. Treatment with any investigational drug within 30 days prior to inclusion
- •8. Pregnancy or breastfeeding
- •9. Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results, incl. limited effort in spiroergometry (CPET).
- •10. Hypersensitivity to the active substance
- •or any of the other ingredients
- •11. Situations where the effect of Ventavis® on platelets may increase the risk of bleeding (e.g. florid ulcer disease, trauma, intracranial bleeding)
- •12. Patients with severe impaired liver function: Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) = 3 × the upper limit of the normal range (ULN) at screening, bilirubin = 3 mg/dL at screening (except for patients with Gilbert‘s syndrome)
- •13. Patients with severe impaired kidney function (creatinine clearance = 30 ml/min)
- •14. Simultaneous participation in another clinical trial with an experimental treatment
- •15. Pulmonal veno-occlusive disease
研究者
相似试验
已完成
3 期
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation StudyHypertension, PulmonaryNCT01469169Bayer27
进行中（未招募）
不适用
Effect of Iloprost inhalation before and during extracorporeal circulation on perioperative morbidity and outcome in high risk cardiac surgical patientsIn this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac surgical patients is investigated in comparison to placebo.MedDRA version: 13.1Level: LLTClassification code 10036727Term: Primary pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-002090-12-DEHospital of the university of munich
已完成
不适用
Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionPulmonary HypertensionNCT03365479University of Giessen30
已完成
3 期
Iloprost in High Risk Cardiac Surgical PatientsPulmonary HypertensionNCT00927654Ludwig-Maximilians - University of Munich253
进行中（未招募）
不适用
Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trialPulmonary arterial hypertension (PAH) is associated with poor prognosis.The most common cause of death is right heart failure. The fact that right heart failure is associated with low systemic perfusion pressures limits the systemic use of potent vasodilators in this patient population. As a consequence, no therapeutic recommendations exist for patients experiencing right heart failure in the course of PAH.EUCTR2007-002803-42-ATniv.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria8